Defence Therapeutics to Engage Investors at December Virtual Life Sciences Forum

Biotechnology innovator Defence Therapeutics (OTCQB: DTCFF) has confirmed its participation in the Life Sciences Virtual Investor Forum, scheduled for December 11th, 2025, where the Montreal-based company will showcase its groundbreaking intracellular delivery technology. Dr. Amie Phinney, Director of Strategy & Business, will present the company’s latest developments directly to a global audience of individual and institutional investors, along with industry advisors and analysts.

Event Details & Registration

The interactive online session commences at 11:00am ET on December 11th, with registration available through VirtualInvestorConferences.com. This virtual forum format enables real-time engagement, allowing investors to pose questions and interact with Defence Therapeutics’ leadership throughout the presentation.

For those unable to attend live, a comprehensive webcast recording will be available post-event. The company encourages early registration and system verification to ensure seamless participation and access to exclusive updates.

Networking Opportunities

Beyond the main presentation, Defence Therapeutics has dedicated time slots for one-on-one investor meetings:

• December 11th: 2:00-5:00pm ET
• December 15th: 10:00-3:00pm ET
• December 16th: 10:00-5:00pm ET

Individual investors and institutional stakeholders can schedule personalized meetings during these windows via the forum’s coordination system.

Defence Therapeutics’ Precision Delivery Technology

At the core of the company’s defence therapeutics forum participation lies the ACCUM® platform—a proprietary intracellular delivery mechanism designed to transport biologics in their native form directly to target cells. This innovation enhances therapeutic potency and efficacy for antibody-based treatments and radiotherapeutic solutions, potentially expanding market accessibility and patient outcomes.

Recent Progress & Strategic Direction

Defence Therapeutics has recently achieved several milestones strengthening its competitive positioning:

In Vivo Validation Success — The company has validated efficacy results from studies evaluating Accum-Kadcyla in breast cancer models, demonstrating the platform’s practical application in oncology.

Operational Expansion — Laboratory capacity and assay capabilities have been expanded to accelerate research and development timelines.

Scientific Leadership — Formation of a robust Scientific Advisory Board has bolstered the company’s technical guidance and credibility within the biotech community.

About Defence Therapeutics Inc.

Defence Therapeutics operates as a specialized biotechnology enterprise headquartered in adMare BioInnovations Technoparc, Montreal. The company’s proprietary intracellular delivery platform represents a differentiated approach to developing more potent, efficacious, and safer biologic therapies. By enabling precision cellular targeting, the ACCUM® technology positions Defence Therapeutics at the forefront of next-generation therapeutic development.

For additional information or investor inquiries:

• Sébastien Plouffe, Chief Executive Officer: (514) 947-2272 | splouffe@defencetherapeutics.com

About Virtual Investor Conferences

Virtual Investor Conferences operates as the preeminent platform for publicly-traded companies to present directly to investors in an interactive digital environment. By replicating traditional on-site conference functionality with enhanced digital capabilities, VIC facilitates targeted one-on-one meetings, professional video integration, and direct investor engagement. The platform serves a diverse network spanning retail investors, institutional stakeholders, and financial professionals globally.